Table 11.
Clinical characteristics between groups based on endocapillary hypercellularity.
| Parameter | Endocapillary Hypercellularity | p-Value | |
|---|---|---|---|
| E0 (N = 56) | E1 (N = 24) | ||
| Age (years) | 40 ± 14 | 37 ± 13 | 0.36 |
| SBP (mmHg) | 129 ± 15 | 137 ± 18 | 0.05 |
| DBP (mmHg) | 79 ± 11 | 82 ± 12 | 0.42 |
| MAP (mmHg) | 94 ± 11 | 98 ± 13 | 0.18 |
| NLR | 2.6 ± 1.7 | 2.1 ± 0.9 | 0.15 |
| PLR | 144 ± 59 | 141 ± 55 | 0.87 |
| Total cholesterol (mg/dL) | 259 ± 110 | 258 ± 89 | 0.97 |
| Triglycerides (mg/dL) | 172 ± 91 | 174 ± 92 | 0.91 |
| Uric acid (mg/dL) | 6.5 ± 1.8 | 6.9± 1.6 | 0.35 |
| Fasting glucose (mg/dL) | 93 ± 12 | 92 ± 10 | 0.87 |
| Serum albumin (g/dL) | 3.5 ± 0.96 | 3.5± 0.8 | 0.9 |
| Total protein (g/dL) | 6.1 ± 1.2 | 5.9± 1.1 | 0.48 |
| Serum creatinine (mg/dL) | 1.4 ± 1.6 | 1.3 ± 0.4 | 0.8 |
| eGFR (mL/min/1.73 m2) | 70 ± 26 | 65 ± 19 | 0.35 |
| UPCR (g/g) | 1.8 ± 2.4 | 1.9 ± 1.5 | 0.92 |
| Erythrocyturia—moderate | 22 (39%) | 11 (46%) | 0.57 |
| Erythrocyturia—severe | 20 (36%) | 8 (34%) | 0.84 |
| Hypertension | 25 (45%) | 8 (58%) | 0.26 |
| ACEI treatment | 35 (63%) | 17 (71%) | 0.47 |
| Immunosuppression use at the time of biopsy | 13 (23%) | 5 (21%) | 0.82 |
| Immunosuppression use after biopsy | 25 (45%) | 13 (54%) | 0.83 |